Annexin A5 as a marker for hepatocellular carcinoma in cirrhotic hepatitis C virus patients

Egyptian Liver Journal

Waleed Mohamed Serag¹  Basem Eysa Elsayed² 

[1]Faculty of Science, Suez University

[2]National Hepatology and Tropical Medicine Research Institute

关键词: AnxA5 level;    HCV;    HCC;    Cirrhosis;   

DOI  :  10.1186/s43066-021-00101-y

来源: DOAJ

【 摘 要 】

Abstract Background The tumorigenesis and development in a variety of cancers is reportedly encouraged via Annexin A5. The levels of Annexin A5 were tested in patients with or without HCC who were affected by liver cirrhosis. The objective of our study was to detect Annexin A5 levels in such patients in order to assess their function as an HCC marker. The longitudinal study comprised 91 cirrhotic HCV patients with and without HCC, and 20 healthy volunteers in the control group approved by the National Hepatology and Tropical Medicine Research Institute (NHTMRI) between March 2017 and August 2018.The serum levels Annexin A5 were found in all groups with ELISA. ANOVA, Mann-Whitney, and χ 2 tests had been applied. Results High scales of Annexin A5 (3.89 + 0.85) were recorded for cirrhosis with HCC, either than cirrhotic patients without HCC (3.06 ± 0.88) (P = 0.041), and either than the control group (0.54 ± 0.11) (P < 0.001). Conclusion In HCV cirrhotic patients with and without HCC, AnxA5 can be used as HCC marker.

【 授权许可】

Unknown